CABALETTA BIO INC
1 day chart
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. It is focused on the discovery and development of engineered T-cell therapies for B-cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company’s product candidates include DSG3-CAART, DSG3/1-CAART, MuSK-CAART, PLA2R-CAART, and FVIII-CAART. DSG3-CAART is evaluated for the treatment of mucosal pemphigus vulgaris (mPV), a subtype of pemphigus vulgaris (PV) that affects the epithelium of the mucous membranes. DSG3/1-CAART is designed for mucocutaneous pemphigus vulgaris (mcPV). MuSK-CAART is designed for the treatment of muscle-specific kinase (MuSK) and myasthenia gravis (MG). PLA2R-CAART is developed to treat phospholipase A2 receptor (PLA2R) associated membranous nephropathy. FVIII-CAART, which is being designed to treat a subset of patients with Hemophilia A.
Buy US stocks in Australia with $0 brokerage and trade CABA today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.